We enable the acceleration of life science research
and development in the pursuit of improved human health

About AiPharma

AiPharma is a biopharmaceutical company developing and commercializing innovative antiviral therapies to treat diseases for unmet patient needs across a broad spectrum of infectious diseases. Our approach lies in matching unmet medical needs with opportunities for more effective solutions that from improvements in established therapies. AiPharma is focused on the clinical and commercial development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV).

Global Response Aid (GRA)

At the stage where COVID-19 was declared a pandemic, we quickly deployed a crew to start an initiative, that later became a full-fledged company called Global Response Aid. Alongside Agility which is one of the world’s leading logistics companies with a presence in 100 countries and annual turnover of $5BN.
 

 
 

PROJECTS

AVIGAN_pack_HR.png

PARTNERS

 

OUR TEAM

alex.jpg

Dr.Alessandro Gadotti 
Chief Executive Officer 

Luca Longobardi
Head of M&A and Corporate Finance

abdulla.jpg

Abdulla Al Mansoori
Executive Director, MENA

richard.jpg

Dr.Richard Kaszynski
Chief Medical Officer

Brett Wight
Chief Commercial Officer

omar.jpg

Omar Arrab

Director

jew.jpg

John White
Group General Counsel

mary.jpg

Mary O’Brian
Global Business Development Director

Adam Fresco
Head of Communications

 

NEWS

 
pr-img.jpg

December 02, 2021

AiPharma Signs Heads of Agreement to Acquire a Controlling Interest in a Pharmaceutical Business with Global Innovation, Manufacturing, Distribution Footprint, and Revenues in Excess of $450 Million 

The transaction is a strategic opportunity to position AiPharma as a fully integrated biotech innovation company

avigan-3-e1633006406825 (1).jpg

October 28, 2021

Fast-Selling COVID-19 Treatment Avigan Made Available in UAE

AiPharma owned Global Response Aid (GRA) and Pharmax, both leading Dubai-based healthcare solutions providers, have partnered to supply the proven COVID-19 treatment, Avigan (Favipiravir), in the UAE. It allows patients with mild to moderate symptoms to be treated at home, easing the pressure on hospitals.

Potential-COVID-19-treatment-to-wrap-up-Phase-III-trial_wrbm_large.jpg

October 26, 2021

Potential COVID-19 treatment to wrap up Phase III trial

Pharmaceutical company Appili Therapeutics has reported the enrollment of the last patient in its Phase III clinical trial to investigate the effectiveness of oral drug Avigan/Reeqonus (favipiravir) to treat COVID-19. The firm recently entered a strategic alliance agreement with AiPharma to develop and advance the drug.

uk-covid-19-patients-able-to-take-gp-prescribed-medicine-at-home.jpg

October 20, 2021

UK COVID-19 patients able to take GP prescribed medicine at home

COVID sufferers in the UK are now able to access a course of tablets from their GP to avoid the need for hospitalisation. AiPharma’s antiviral treatment, favipiravir, is currently taken orally over a course of 7-14 days.

pr-img.jpg

October 5, 2021

AiPharma Signs Binding Agreement To Sell To Aditxt Inc (Nasdaq: ADTX).

DUBAI, United Arab Emirates, Oct. 5, 2021 /PRNewswire/ -- AiPharma Global Holdings LLC ("AiPharma") a company focused on discovering, developing and commercializing antiviral therapies across a broad spectrum of infectious diseases today announced it has entered a binding agreement

ezgif.com-gif-maker.jpg

September 29, 2021

AiPharma Enters into Strategic Alliance and Stock Swap Agreement with Appili Therapeutics

AiPharma Global Holdings LLC ("AiPharma"), a private biopharmaceutical research, development, and commercialization company, and Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) ("Appili"), a biopharmaceutical company.

avigan.jpg

September 23, 2020

Avigan® Shows Promising Results in Treatment of COVID Patients in Japan

Healthcare solutions provider Global Response Aid (GRA) and Dr. Reddy's Laboratories (NYSE: RDY) announced that the anti-viral drug Avigan® produced promising results in a single-blinded, placebo-controlled Phase 3 clinical study conducted in Japan with the sponsorship of FujiFilm Toyama Chemical.

japan.jpg

September 23, 2020

Anti-influenza drug Avigan® TabletMeets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients

TOKYO, September 23, 2020—FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada; hereinafter “FUJIFILM Toyama Chemical”) has announced today that primary endpoint has been met in phase III clinical trial of “Avigan Tablet” 

dr.jpg

September 20, 2020

International Cooperation in Clinical Studies: Richard H. Kaszynski / MD, Ph.D., Co-Founder and Director of Stanford Solutions

Richard H. Kaszynski formed a global network to rapidly conduct clinical drug trials in order to fight against infectious disease pandemics. He talks about a promising drug candidate for COVID-19.

 

CONTACT US